DelveInsight has launched a new report on  Essential Thrombocythemia Market Insights, Epidemiology and Market Forecast-2030

DelveInsight’s ‘Essential Thrombocythemia – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Essential Thrombocythemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Essential Thrombocythemia (ET) belongs to a group of diseases called myeloproliferative neoplasms, which cause the bone marrow to make excessive platelets, white blood cells, and/or red blood cells. The signs and symptoms vary from person to person, but most people with ET do not have any symptoms when the platelet cell count first increases. Signs and symptoms that develop as the disease progresses include:

 Increased production of megakaryocytes (a type of cell in the bone marrow that is responsible for
making platelets);
 enlargement of the spleen (splenomegaly); and
 bleeding in several parts of the body and/or clotting episodes such as strokes, pain in the legs, and
difficulty in breathing.

The most commonly mutated genes in ET are JAK2 and CALR; the MPL, THPO, and TET2 genes can also be altered in this condition. The JAK2, MPL, and THPO genes provide instructions for making proteins that promote the growth and division (proliferation) of blood cells. Mutations in the JAK2, MPL, and THPO genes that are associated with ET lead to overactivation of the JAK/STAT pathway. The abnormal activation of JAK/STAT signaling leads to overproduction of megakaryocytes, which results in an
increased number of platelets. Excess platelets can cause thrombosis, which further leads to many signs and symptoms of ET; mutations in the CALR and TET2 genes have been found in people with ET.

 

 

Request for :- Essential Thrombocythemia free sample page

 

Essential Thrombocythemia Epidemiology

The Essential Thrombocythemia epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Essential Thrombocythemia epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Essential Thrombocythemia epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Report Key Facts:- 

1. Fewer than 1 in 100,000 people are diagnosed with ET in any year (the most recent estimates range from 0.38–1.7 per 100,000). Women are more likely to be diagnosed with ET than men, although the reason for this is unknown

2. According to the US National library of medicine, ET affects an estimated 1–24 per 1 million people worldwide.

3. ET is exceedingly rare in children and typically occurs as an inherited genetic disorder. In adults, the genetic mutations typically identified in ET are not inherited, and instead, are acquired genetic accidents (known as an acquired mutation) that happen during an individual’s lifetime.

 

Report Scope:- 

• The Essential Thrombocythemia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Essential Thrombocythemia Epidemiology Report and Model provide an overview of the risk factors and global trends of Essential Thrombocythemia in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight about the historical and forecasted patient pool of Essential Thrombocythemia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Essential Thrombocythemia
• The report provides the segmentation of the Essential Thrombocythemia epidemiology

 

“As per the study conducted by Brière et al. titled “Essential thrombocythemia,” ET is an acquired myeloproliferative disorder (MPD) characterized by a sustained elevation of platelet number with a tendency for thrombosis and hemorrhage. The prevalence in the general population is approximately 30 per 100,000. The median age at diagnosis is 65–70 years, but the disease may occur at any age. The female to male ratio is about 2:1”

 

Major Key Companies working on Essential Thrombocythemia that are given below:- 

1. Shire Pharma Co. 

2. AOP Orphan Pharmaceuticals 

3. Imago BioSciences

 

Name of drugs covered are given below:- 

1. Agrylin (Xagrid

2. Thromboreductin:

3. IMG-7289

 

Table of Contents

1. Key Insights 

2. Executive Summary of Essential Thrombocythemia

3.  Essential Thrombocythemia: Disease Background and Overview

4. Patient Journey

5. Epidemiology and Patient Population

6. Treatment Algorithm, Current Treatment, and Medical Practices

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

Why should you buy this Essential Thrombocythem market report?

• The Essential Thrombocythemia Epidemiology report will allow the user to –
• Develop business strategies by understanding the trends shaping and driving the global Essential Thrombocythemia market
• Quantify patient populations in the global Essential Thrombocythemia market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Essential Thrombocythemia therapeutics in each of the markets covered
• Understand the magnitude of Essential Thrombocythemia population by its epidemiology
• The Essential Thrombocythemia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

 

Related Reports :- 

1. Essential Thrombocythemia Pipeline Insights, 2020

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/